01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported third-quarter 2024 results in this Form 10-Q filed October 31, 2024.
Total revenues for the three months ended September 30, 2024 were $290.1 milliona, up from $216.0 million a year earlier, and net income was $137.0 million, or $1.05 per diluted share, compared with $81.8 million, or $0.61 per diluted share, in the prior-year quarter. Royalties rose to $155.1 million from $114.4 million, driven by sales uptake of DARZALEX SC by Janssen and Phesgo by Roche, and revenues under collaborative agreements increased to $48.4 million, including a $27.0 million upfront license and target nomination fee. For the nine months ended September 30, 2024, total revenues were $717.3 million and net income was $307.1 million.
At September 30, 2024, cash, cash equivalents and marketable securities totaled $666.3 millionb, and the company stated this is sufficient to fund operations for at least the next twelve months. Total assets were $2.12 billion and total stockholders' equity was $452.7 million, compared with $83.8 million at December 31, 2023. Long-term debt, net was $1.50 billion, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028, both with principal of $1.525 billion in total.
Net cash provided by operating activities for the nine months was $300.6 millionc. The company completed a $750.0 million capital return program in June 2024 and authorized a new $750.0 million repurchase program in February 2024; no shares were repurchased in the third quarter of 2024.
The filing also highlights recent partner milestones, including the September 2024 expansion of argenx's collaboration to six targets with $30.0 milliond in upfront payments, FDA approval of OCREVUS ZUNOVO with ENHANZE, and FDA approval of TECENTRIQ HYBREZA with ENHANZE, which resulted in a $12.0 million milestone payment. The company states that it is not a party to any legal proceedings expected to have a material adverse effect.
02—Key points
Key Highlights
- Total revenues for Q3 2024 were $290.1 million, up from $216.0 million in Q3 2023; nine-month revenues were $717.3 million versus $599.2 million.
- Royalties increased to $155.1 million in Q3 2024 from $114.4 million, driven by DARZALEX SC (Janssen) and Phesgo (Roche) sales uptake.
- Net income for Q3 2024 was $137.0 million, or $1.05 per diluted share, compared with $81.8 million, or $0.61 per diluted share, a year earlier.
- Cash, cash equivalents and marketable securities totaled $666.3 million at September 30, 2024, which the company says will fund operations for at least twelve months.
- Total stockholders' equity rose to $452.7 million from $83.8 million at December 31, 2023, reflecting nine-month net income of $307.1 million.
- Long-term debt, net was $1.50 billion against $1.525 billion principal of convertible notes due 2027 and 2028; the $750.0 million revolving credit facility was undrawn.
- No share repurchases were made in Q3 2024, and a new $750.0 million repurchase program was authorized in February 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Halozyme Therapeutics kept $0.47.
- Revenue$290.1M100.0%
- Cost of revenue−$49.4M17.0%
- Gross profit$240.7M83.0%
- Operating costs−$77.5M26.7%
- Operating income$163.2M56.3%
- Interest, other & tax−$26.2M9.0%
- Net income$137.0M47.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $290.08M$216.03M | +34.3% |
| Cost of Revenue | $49.43M$54.82M | −9.8% |
| Gross Profit | $240.66M$161.21M | +49.3% |
| R&D Expenses | $18.46M$17.32M | +6.6% |
| SG&A Expenses | $41.24M$35.27M | +16.9% |
| Operating Expenses | $126.89M$127.75M | −0.7% |
| Operating Income | $163.20M$88.28M | +84.9% |
| Net Income | $137.01M$81.84M | +67.4% |
| EPS (Basic) | $1.08$0.62 | +74.2% |
| EPS (Diluted) | $1.05$0.61 | +72.1% |
| Shares Outstanding (Basic) | 126.85M131.97M | −3.9% |
| Shares Outstanding (Diluted) | 130.13M134.08M | −2.9% |
05—Questions
Frequently Asked Questions
What drove the increase in Halozyme's revenue in the third quarter of 2024?
Royalties rose to $155.1 million from $114.4 million, primarily from continued sales uptake of DARZALEX SC by Janssen and Phesgo by Roche, and from the prior-year launch of VYVGART Hytrulo by argenx. Revenues under collaborative agreements increased to $48.4 million from $15.0 million, mainly due to the timing of milestones, including a $27.0 million upfront license and target nomination fee.
How much cash and liquidity does the company report?
As of September 30, 2024, cash, cash equivalents and marketable securities totaled $666.3 million. The company believes this will be sufficient to fund operations for at least the next twelve months, and its revolving credit facility was undrawn.
What is the company's debt position?
Long-term debt, net was $1.50 billion at September 30, 2024. This consists of the 0.25% Convertible Notes due 2027 ($805.0 million principal) and the 1.00% Convertible Notes due 2028 ($720.0 million principal), with an unamortized debt discount of $20.8 million. The company stated it was in compliance with all covenants.
What did the company say about share repurchases?
The company completed its $750.0 million capital return program in June 2024, having repurchased 19.1 million shares over three years. In February 2024 the Board authorized a new program to repurchase up to $750.0 million of common stock, but no shares were repurchased during the third quarter of 2024.
What partner developments were highlighted in the filing?
In September 2024, argenx expanded its collaboration to six exclusive targets with $30.0 million in upfront payments, and the FDA approved OCREVUS ZUNOVO and TECENTRIQ HYBREZA with ENHANZE. The TECENTRIQ HYBREZA approval triggered a $12.0 million milestone payment to the company.
06—Continue